An immunotherapy study suggests hopeful results for advanced melanoma patients. The study indicated that relatlimab and nivolumab elicited beneficial responses in patients with late-stage melanoma. Specifically, the phase 2-3 trial indicated that combination therapy extended progression free-survival despite an individual’s prognostic indicators. Through using both antibodies to inhibit two immune checkpoint pathways, greater immune response was stimulated against cancer cells. Continued research is centered on the effects of combination therapy for patients in different stages of melanoma progression.